Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;33(3):322-30.
doi: 10.5152/balkanmedj.2016.141173. Epub 2016 May 1.

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

Sedat Üstündağ  1 , Ekrem Doğan  2 , Murat Duranay  3 , Rümeyza Kazancıoğlu  4 , Vedat Çelik  5 , Abdülkadir Ünsal  6 , Lütfullah Altıntepe  7 , Belda Dursun  8 , Ertuğrul Akbaş  9 , Fatih Özdener  9 , Alaattin Yıldız  10
Affiliations

Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients

Sedat Üstündağ et al. Balkan Med J. 2016 May.

Abstract

Background: We investigated the efficacy, safety and tolerability of once-monthly administration of C.E.R.A. in erythropoiesis stimulating agents (ESAs) naive predialysis patients with CKD for anemia treatment.

Study design: Single arm, open label study.

Methods: A total of 75 patients (mean (SD) age was 52.8 (16.4) years, 76.0% were female) were included in this study conducted between 12 August 2008 and 30 October 2009 in 9 centers across Turkey. The mean change in Hb concentration (g/dL) between baseline (week 0) and the efficacy evaluation period (EEP) was the primary efficacy parameter evaluated in three consecutive periods including a dose titration period (DTP; with initial 1.2 μg/kg dose of C.E.R.A., subcutaneously, 28 weeks), EEP (8 weeks) and a long-term safety period (16 weeks).

Results: Our analysis revealed an improvement in Hb levels from baseline value of 9.4 (0.4) g/dL to time adjusted average level of 11.4 (0.7) g/dL in EEP in the per protocol (PP) population and from 9.3 (0.5) g/dL to 11.1 (1.0) g/dL in intent-to-treat (ITT) population. Mean (SD) change in Hb levels from baseline to EEP was 2.0 (0.7) g/dl in the PP population (primary endpoint) and 1.7 (1.1) g/dL in the ITT population. The percentage of patients whose Hb concentrations remained within the target range of 10.0-12.0 g/dL throughout the EEP was 43.9% (95% CI: 28.5-60.3%) in the PP population and 38.7% (95% CI: 27.6% to 50.6%) in the ITP population. A total of 206 adverse events (AE) were reported in 77.0% of patients with hypertension (20%) as the most frequent AE.

Conclusion: Once-monthly subcutaneous C.E.R.A. administration is effective and safe in the treatment of anemia in pre-dialysis patients with CKD, who are not currently treated with ESAs.

Keywords: C.E.R.A.; chronic kidney disease; efficacy; hemoglobin levels; safety; tolerability.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Patient disposition
FIG. 2.
FIG. 2.
Hemoglobin levels in the safety population (n=75)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the third National Health and Nutrition Examination Survey (1988–1994) Arch Intern Med. 2002;162:1401–8. http://dx.doi.org/10.1001/archinte.162.12.1401. - DOI - PubMed
    1. IV. NKF-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis. 2001;37(1 Suppl 1):S182–238. http://dx.doi.org/10.1016/S0272-6386(01)70008-X. - DOI - PubMed
    1. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 1999;14(Suppl 5):1–50. - PubMed
    1. Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, et al. Ba16285 Study Investigators Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clin Ther. 2007;29:626–39. http://dx.doi.org/10.1016/j.clinthera.2007.04.014. - DOI - PubMed
    1. Macdougall IC. Anaemia and chronic renal failure. Medicine. 2011;39:425–9. http://dx.doi.org/10.1016/j.mpmed.2011.04.009. - DOI

LinkOut - more resources